tiprankstipranks
Advertisement
Advertisement

CRDF Stock Latest News

Cardiff Oncology appoints new CEO, CFO and COO
Company AnnouncementsCardiff Oncology appoints new CEO, CFO and COO
4d ago
8K
CRDF
Cardiff Oncology appoints Mani Mohindru CEO, Josh Muntner CFO
PremiumThe Fly
Cardiff Oncology appoints Mani Mohindru CEO, Josh Muntner CFO
4d ago
ACRS
CRDF
Cardiff Oncology Formalizes Executive Departures Amid Strategic Review
PremiumCompany Announcements
Cardiff Oncology Formalizes Executive Departures Amid Strategic Review
11d ago
8K
CRDF
Cardiff Oncology advances onvansertib program in colorectal cancer
PremiumCompany Announcements
Cardiff Oncology advances onvansertib program in colorectal cancer
2M ago
8K
CRDF
Cardiff Oncology price target lowered to $6 from $10 at Piper Sandler
PremiumThe Fly
Cardiff Oncology price target lowered to $6 from $10 at Piper Sandler
2M ago
CRDF
Cardiff Oncology: Promising Onvansertib Data and Solid Cash Runway Support Buy Rating and $10 Price Target
PremiumRatingsCardiff Oncology: Promising Onvansertib Data and Solid Cash Runway Support Buy Rating and $10 Price Target
2M ago
CRDF
CRDF Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Premium
Pre-Earnings
CRDF Earnings Report this Week: Is It a Buy, Ahead of Earnings?
2M ago
CRDF
Cardiff Oncology selloff brings attractive entry point, says H.C. Wainwright
Premium
The Fly
Cardiff Oncology selloff brings attractive entry point, says H.C. Wainwright
3M ago
CRDF
Cardiff Oncology Overhauls Leadership to Advance Onvansertib
PremiumCompany Announcements
Cardiff Oncology Overhauls Leadership to Advance Onvansertib
3M ago
8K
CRDF
Balancing Leadership Turmoil and Focused Clinical Strategy: Maintaining a Buy on Cardiff Oncology’s Onvansertib Amid Catalyst-Rich Outlook
PremiumRatings
Balancing Leadership Turmoil and Focused Clinical Strategy: Maintaining a Buy on Cardiff Oncology’s Onvansertib Amid Catalyst-Rich Outlook
3M ago
CRDF
Cardiff Oncology announces CEO Erlander, CFO Levine have stepped down
PremiumThe Fly
Cardiff Oncology announces CEO Erlander, CFO Levine have stepped down
3M ago
CRDF
Cardiff Oncology announces update from CRDF-004, Phase 2 trial of onvansertib
PremiumThe Fly
Cardiff Oncology announces update from CRDF-004, Phase 2 trial of onvansertib
3M ago
CRDF
Cardiff Oncology initiated with an Outperform at Noble Capital
PremiumThe FlyCardiff Oncology initiated with an Outperform at Noble Capital
3M ago
CRDF
Cardiff Oncology: Promising Clinical Results and Strong Financial Position Justify Buy Rating
Premium
Ratings
Cardiff Oncology: Promising Clinical Results and Strong Financial Position Justify Buy Rating
5M ago
CRDF
Cardiff Oncology Reports Increased Losses Amid Ongoing Trials
Premium
Company Announcements
Cardiff Oncology Reports Increased Losses Amid Ongoing Trials
5M ago
CRDF
Cardiff Oncology’s Promising Future: Buy Rating Backed by Strong Financials and Onvansertib’s Clinical Success
PremiumRatings
Cardiff Oncology’s Promising Future: Buy Rating Backed by Strong Financials and Onvansertib’s Clinical Success
5M ago
CRDF
Cardiff Oncology raises FY25 revenue view to $76M-$78M from $72M-$76M
PremiumThe Fly
Cardiff Oncology raises FY25 revenue view to $76M-$78M from $72M-$76M
5M ago
CRDF
Cardiff Oncology reports Q3 EPS (17c), consensus (21c)
PremiumThe Fly
Cardiff Oncology reports Q3 EPS (17c), consensus (21c)
5M ago
CRDF
CRDF Earnings this Week: How Will it Perform?
PremiumPre-Earnings
CRDF Earnings this Week: How Will it Perform?
6M ago
CRDF
Largest borrow rate increases among liquid names
PremiumThe FlyLargest borrow rate increases among liquid names
7M ago
ACB
BHP
Largest borrow rate increases among liquid names
Premium
The Fly
Largest borrow rate increases among liquid names
8M ago
KKR
ARKK
Buy Rating Maintained for Cardiff Oncology Despite Increased Risk Profile of Onvansertib
Premium
Ratings
Buy Rating Maintained for Cardiff Oncology Despite Increased Risk Profile of Onvansertib
8M ago
CRDF

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >